Nexobrid

Generic name: anacaulase-bcdb

Used for: Removing dead skin from deep burns (eschar)

How do you pay?

How to pay the least

Ask for the cash price

Nexobrid

Nexobrid is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Nexobrid’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameNexobrid
Authorized genericanacaulase-bcdb
Regular genericanacaulase-bcdb
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Nexobrid?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Nexobrid’s maker. Ask the pharmacy for Nexobrid’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Nexobrid itself, from the same company, sold without the brand name, and usually for less. For now Nexobrid is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Nexobrid is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Nexobrid’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

NEXOBRID contains proteolytic enzymes and is indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

  • Chemical or electrical burns.
  • Burns on the face, perineum, or genitalia.
  • Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease.
  • Circumferential burns.
  • Burns in patients with significant cardiopulmonary disease, including inhalation injury.

NEXOBRID is not recommended for:

  • Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
  • Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal.

Source: the FDA label for Nexobrid (Vericel Corporation), September 11, 2025. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/nexobrid/